文献速递脑血管病

探索非心源性轻中度缺血性卒中或高危短暂性脑缺血发作患者双联抗血小板治疗结局的性别差异:READAPT研究队列的倾向性匹配分析

Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort.
PubMed 文献 · Stroke · 2024-12-09

基于前瞻性多中心队列READAPT的倾向性匹配分析,纳入1643例发病48小时内启动双联抗血小板治疗的非心源性轻中度缺血性卒中或高危短暂性脑缺血发作患者,匹配531对男女。女性90天新发缺血性卒中或其他血管事件风险显著低于男性(HR 0.53,95%CI 0.28-0.99,P=0.039),安全结局极低且无性别差异。

要点

  • 女性90天新发缺血性卒中或其他血管事件风险显著低于男性(HR 0.53,95%CI 0.28-0.99,P=0.039)。
  • 90天中重度出血女性0.4% vs 男性0.8%(P=0.413),症状性颅内出血女性0.2% vs 男性0.4%(P=0.563),均无显著差异。
  • 亚组分析显示女性在年龄<50岁、基线NIHSS 0-5分、病前mRS<2分、大动脉粥样硬化病因及无糖尿病患者中90天新发缺血性卒中或其他血管事件风险更低。

核心结论

  • 作者认为,接受双联抗血小板治疗的非心源性轻中度卒中或高危短暂性脑缺血发作女性患者,其短期复发缺血事件风险可能低于男性。
  • 作者指出需要进一步研究以理解双联抗血小板治疗后结局潜在性别差异背后的机制。

研究设计与样本

  • 研究为前瞻性多中心队列研究READAPT的倾向性匹配分析。
  • 纳入非心源性轻中度卒中(NIHSS评分0-10分)或高危短暂性脑缺血发作(ABCD2≥4分)且在症状发作48小时内启动双联抗血小板治疗的患者。
  • 从READAPT研究队列2278例患者中纳入1643例接受双联抗血小板治疗的轻中度卒中或高危短暂性脑缺血发作患者(平均年龄69.8±12.0岁;女性34.3%),匹配531对女性和男性。
  • 主要有效性结局为90天新发缺血性卒中或其他血管事件风险。
  • 次要有效性结局为90天改良Rankin量表评分序贯移位、血管性和全因死亡率、24小时早期神经功能改善或恶化。

主要发现

  • 女性90天新发缺血性卒中或其他血管事件风险显著低于男性(HR 0.53,95%CI 0.28-0.99;P=0.039)。
  • 次要有效性结局在男女间无显著差异。
  • 90天安全结局风险极低且男女间无差异:中重度出血女性0.4% vs 男性0.8%(P=0.413);症状性颅内出血女性0.2% vs 男性0.4%(P=0.563)。
  • 主要有效性结局亚组分析显示,在年龄<50岁、基线NIHSS评分0-5分、病前mRS评分<2分、大动脉粥样硬化病因及无糖尿病的女性中,90天新发缺血性卒中或其他血管事件风险更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步研究以理解双联抗血小板治疗后结局潜在性别差异背后的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sex may impact clinical outcomes in patients with stroke treated with dual antiplatelet therapy (DAPT). We aimed to investigate the sex differences in the short-term outcomes of DAPT within a real-world population of patients with noncardioembolic mild-to-moderate ischemic stroke or high-risk transient ischemic attack. METHODS: We performed a propensity score-matched analysis from a prospective multicentric cohort study (READAPT [Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]) by including patients with noncardioembolic mild-to-moderate stroke (National Institutes of Health Stroke Scale score of 0-10) or high-risk transient ischemic attack (age, blood pressure, clinical features, duration of transient ischemic attack, presence of diabetes [ABCD2] ≥4) who initiated DAPT within 48 hours of symptom onset. The primary effectiveness outcome was the 90-day risk of new ischemic stroke or other vascular events. The secondary effectiveness outcomes were the 90-day modified Rankin Scale score ordinal shift, vascular and all-cause mortality, and 24-hour early neurological improvement or deterioration. The safety outcomes included the 90-day risk of moderate-to-severe and any bleeding, symptomatic intracranial hemorrhage, and 24-hour hemorrhagic transformation. Outcomes were compared between sexes using Cox and generalized ordinal logistic regression analyses, along with calculating risk differences and ratios. RESULTS: From 2278 patients in the READAPT study cohort, we included 1643 mild-to-moderate strokes or high-risk transient ischemic attacks treated with DAPT (mean age, 69.8±12.0 years; 34.3% women). We matched 531 women and men. The 90-day risk of new ischemic stroke or other vascular events was significantly lower among women than men (hazard ratio, 0.53 [95% CI, 0.28-0.99]; P=0.039). There were no significant differences in secondary effectiveness outcomes. The 90-day risk of safety outcomes was extremely low and did not differ between women and men (moderate-to-severe bleedings: 0.4% versus 0.8%; P=0.413; symptomatic intracranial hemorrhage: 0.2% versus 0.4%; P=0.563). Subgroup analysis for primary effectiveness outcome showed a lower 90-day risk of new ischemic stroke or other vascular events among women aged <50 years, baseline National Institutes of Health Stroke Scale score of 0 to 5, prestroke modified Rankin Scale score <2, large artery atherosclerosis cause, and no diabetes. CONCLUSIONS: Our findings suggest that women with noncardioembolic mild-to-moderate stroke or high-risk transient ischemic attack treated with DAPT may have lower short-term risk of recurrent ischemic events than men. Further research is needed to understand the mechanisms behind potential sex-based differences in outcomes after DAPT use. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05476081.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Foschi M, D'Anna L, De Matteis E, et al. Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort. Stroke. 2024. PMID: 39648888. doi:10.1161/STROKEAHA.124.049210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。